Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -168% Improvement Relative Risk Favipiravir for COVID-19  Saito et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 132 patients in Japan (February 2020 - June 2021) Higher mortality with favipiravir (not stat. sig., p=0.063) c19early.org Saito et al., Infection Prevention in .., Jan 2024 Favors favipiravir Favors control

Predictors of in-hospital mortality in elderly unvaccinated patients during SARS-CoV-2 Alpha variants epidemic

Saito et al., Infection Prevention in Practice, doi:10.1016/j.infpip.2024.100341
Jan 2024  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 132 hospitalized COVID-19 patients over age 65 in Japan during the Alpha variant surge, showing higher mortality with favipiravir in unadjusted results, without statistical significance.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 168.3% higher, RR 2.68, p = 0.06, treatment 7 of 40 (17.5%), control 6 of 92 (6.5%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Saito et al., 28 Jan 2024, retrospective, Japan, peer-reviewed, 6 authors, study period February 2020 - June 2021, average treatment delay 6.9 days. Contact: zyst_0404@yahoo.co.jp.
This PaperFavipiravirAll
Predictors of in-hospital mortality in elderly unvaccinated patients during SARS-CoV-2 Alpha variants epidemic
Zenya Saito, Shota Uchiyama, Saiko Nishioka, Kentaro Tamura, Nobumasa Tamura, Kazuyoshi Kuwano
Infection Prevention in Practice, doi:10.1016/j.infpip.2024.100341
Background: COVID-19, caused by SARS-CoV-2, has caused a global pandemic. This study aimed to identify predictors of in-hospital mortality in unvaccinated elderly patients with COVID-19 by comparing various predictive factors between the survivors and nonsurvivors. Methods: We retrospectively selected 132 unvaccinated patients aged over 65 years with COVID-19 at a hospital in Kanagawa, Japan, during SARS-CoV-2 Alpha variants epidemic. We compared the clinical characteristics, laboratory and radiological findings, treatment, and complications of the survivors and non-survivors. In logistic regression analysis, variables that were significant in the univariate analysis were subjected to multivariate analysis using the variable increase method. Results: There were 119 and 13 patients in the survivor and non-survivor groups, respectively. Multivariate regression revealed increasing odds with the presence of ARDS and DIC (odd ratio (OR) ¼ 16.35, 34.36; P¼0.002, 0.001, respectively) and prolonged hospital stay (OR ¼ 1.17; P¼0.004). Conclusions: We found the complications of ARDS and DIC and hospital length of stay to be independent predictors of in-hospital mortality in elderly unvaccinated patients with COVID-19. Establishing treatments and prevention methods for ARDS and DIC could result in lower mortality rates.
Credit author statement Zenya Saito: Conceptualization, Original draft, Writing, Reviewing and Editing. Shota Uchiyama: Data collection, investigation, reviewing final manuscript. Saiko Nishioka: Data collection, investigation, reviewing final manuscript. Kentaro Tamura: Data collection, investigation, reviewing final manuscript. Nobumasa Tamura: Data collection, investigation, reviewing final manuscript. Kazuyoshi Kuwano: Validation, Methodology, Data analysis, Supervision. Conflict of interest statement The authors declare that they have no competing interests.
References
Albitar, Ballouze, Ooi, Ghadzi, Risk factors for mortality among COVID-19 patients, Diabetes Res Clin Pract
Ards Definition, Force, Ranieri, Rubenfeld, Thompson et al., Acute respiratory distress syndrome: the Berlin Definition, JAMA
Asakura, Ogawa, COVID-19-associated coagulopathy and disseminated intravascular coagulation, Int J Hematol
Asakura, Takahashi, Uchiyama, Eguchi, Okamoto et al., Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis, Thromb J
Beitler, Shaefi, Montesi, Devlin, Loring et al., Prone positioning reduces mortality from acute respiratory distress syndrome in the low tidal volume era: a meta-analysis, Intensive Care Med
Buising, Thursky, Black, Macgregor, Street et al., A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia, Thorax
Chalmers, Crichton, Goeminne, Cao, Humbert et al., Management of hospitalized adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline, Eur Respir J
Coppo, Bellani, Winterton, Pierro, Soria et al., Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study, Lancet Respir Med
Ding, Li, Chen, Shu, Song et al., Association of liver abnormalities with in-hospital mortality in patients with COVID-19, J Hepatol
Freund, Lemachatti, Krastinova, Van Laer, Claessens et al., Prognostic accuracy of sepsis-3 criteria for inhospital mortality among patients with suspected infection presenting to the emergency department, JAMA
Huang, Pranata, Lim, Oehadian, Alisjahbana, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis, Ther Adv Respir Dis
Inoue, Yamamoto, Identification of an existing Japanese pancreatitis drug, nafamostat, which is expected to prevent the transmission of new coronavirus infection (COVID-19
Kasamatsu, Yamaguchi, Kawaguchi, Tanaka, Oka et al., Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia, Respirol
Lambden, Laterre, Levy, Francois, The SOFA scoreddevelopment, utility and challenges of accurate assessment in clinical trials, Crit Care
Li, Xu, Yu, Wang, Tao et al., Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan, J Allergy Clin Immunol
Osterbur, Mann, Kuroki, Declue, Multiple organ dysfunction syndrome in humans and animals, J Vet Intern Med
Shindo, Sato, Maruyama, Ohashi, Ogawa et al., Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia, Respirol
Singer, Deutschman, Seymour, Shankar-Hari, Annane et al., The third international consensus definitions for sepsis and septic shock (Sepsis-3), JAMA
Tabata, Imai, Kawano, Ikeda, Kodama et al., Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis, Lancet Infect Dis
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost
Thachil, Tang, Gando, Falanga, Cattaneo et al., ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J Thromb Haemost
Toma, Abu-Hanna, Bosman, Discovery and inclusion of SOFA score episodes in mortality prediction, J Biomed Inform
Wang, Zhang, Yu, Tao, Xie, 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study, Intensive Care Med
Wang, Zhao, Zai, Li, Cross-species transmission of the newly identified coronavirus 2019-nCoV, J Med Virol
Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus Disease 2019 pneumonia in Wuhan, China, JAMA Intern Med
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med
Zhang, Cao, Tan, Dong, Wang et al., Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients, Allergy
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit